Physician profile
Crystal Hlaing
NPI 1366735896
$3,396.39
in general payments reported to CMS, 2019-2025
22 companies · $1,649 in 2025
The $1,649 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $85.36 · 2021: $21.62 · 2022: $68.42 · 2023: $394 · 2024: $310 · 2025: $1,649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $1,484.76 | 2025 | Rapiblyk |
| Abbvie INC. | $254.56 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $250.03 | 2019-2023 | Dificid |
| Janssen Pharmaceuticals, INC | $223.40 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $194.08 | 2019-2020 | |
| Pfizer INC. | $150.16 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.89 | 2019-2024 | Jardiance |
| Csl Behring | $112.67 | 2019-2023 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $101.54 | 2023 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $88.16 | 2019 | |
| Ferring Pharmaceuticals INC. | $87.65 | 2023-2024 | Rebyota |
| Vifor Pharma, INC. | $67.98 | 2019-2023 | Veltassa |
| Astellas Pharma US INC | $60.74 | 2019-2022 | |
| Shionogi INC | $39.93 | 2023-2024 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $39.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.04 | 2019 | |
| Inari Medical, INC. | $22.69 | 2022 | |
| Eusa Pharma (US) LLC | $19.16 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.26 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.60 | 2019 | |
| Mylan Specialty L.P. | $14.23 | 2019 | |
| Aimmune Therapeutics, INC. | $13.99 | 2025 | Vowst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Hlaing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.